Program:
Overview of significant clinical aspects presented during the meeting, including:

• Update of the ASCEND-CML study of frontline asciminib: High rate of optimal response and resistance due to mutations (Yeung D et al.) (02:41)
• Asciminib demonstrates favorable safety and tolerability compared with each investigator-selected TKI in newly diagnosed CML-CP in the pivotal Phase 3 ASC4FIRST study: Week 96 update (Cortes J et al.) (06:47)
• Efficacy and safety of asciminib in CP-CML: Interim results from the Phase 2 ASCESCALATE trial in the cohort of patients after 1 prior TKI (Cortes J et al.) (12:12)
• 18-months follow-up of the trial of imatinib after ponatinib induction (TIPI) in the front-line treatment of CP-CML (Nicolini F et al.) (15:40)
• Safety and efficacy of Tgrx-678, a BCR::ABL 1 allosteric inhibitor (Jiang Q et al.) (19:14)
• Olverembatinib as second-line therapy in patients with chronic-phase CML (Weiming L et al.) (20:37)

If you have any questions or comments to the speaker, please email info@cml-foundation.org.